Operating Segments (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Summary of segmental information
Revenues	$ 1,330,884	$ 2,630,986
Income/(Loss) from Operations	(1,738,190)	(1,905,705)
Amortization and Depreciation Expense	21,050	22,607
Interest Income (Expense), Net	4,753	756,272
Share-Based Compensation	146,627	136,411
Identifiable Assets	8,409,210		$ 10,267,105
Vaccines/BioDefense [Member]
Summary of segmental information
Revenues	1,330,884	2,630,986
Income/(Loss) from Operations	136,600	317,991
Amortization and Depreciation Expense	9,769	10,019
Share-Based Compensation	17,998	28,006
Identifiable Assets	1,073,536		1,297,986
BioTherapeutics [Member]
Summary of segmental information
Revenues
Income/(Loss) from Operations	(1,027,555)	(1,245,585)
Amortization and Depreciation Expense	9,567	10,433
Share-Based Compensation	49,770	34,832
Identifiable Assets	43,320		49,422
Corporate [Member]
Summary of segmental information
Income/(Loss) from Operations	(847,235)	(978,111)
Amortization and Depreciation Expense	1,714	2,155
Interest Income (Expense), Net	4,753	(3,885)
Share-Based Compensation	78,859	$ 73,573
Identifiable Assets	$ 7,292,354		$ 8,919,698